Vitrolife (VITRS) Stock Overview
Provides assisted reproduction products in Europe, the Middle East, Africa, Asia-Pacific, and the Americas. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
VITRS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Vitrolife AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 134.70 |
| 52 Week High | SEK 176.60 |
| 52 Week Low | SEK 134.70 |
| Beta | 1.77 |
| 1 Month Change | -2.46% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -13.98% |
| 5 Year Change | -42.68% |
| Change since IPO | -1.17% |
Recent News & Updates
Recent updates
Shareholder Returns
| VITRS | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -2.5% | 9.0% | 2.2% |
| 1Y | n/a | 9.8% | 13.4% |
Return vs Industry: Insufficient data to determine how VITRS performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how VITRS performed against the UK Market.
Price Volatility
| VITRS volatility | |
|---|---|
| VITRS Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.1% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.7% |
| 10% least volatile stocks in GB Market | 2.5% |
Stable Share Price: VITRS's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine VITRS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 1,147 | Bronwyn Brophy O´Connor | www.vitrolife.com |
Vitrolife AB (publ) provides assisted reproduction products in Europe, the Middle East, Africa, Asia-Pacific, and the Americas. It offers sperm processing, oocyte retrieval needles, micromanipulation pipettes, time-lapse systems, and evaluation tools, laser and imaging systems, IVF media and oil, embryo transfer, cryopreservation, and genomics kits. The company also provides eWitness and Labware products, such as dishes, pipettes, tubes, and VitroTemp.
Vitrolife AB (publ) Fundamentals Summary
| VITRS fundamental statistics | |
|---|---|
| Market cap | SEK 18.57b |
| Earnings (TTM) | SEK 455.00m |
| Revenue (TTM) | SEK 3.54b |
Is VITRS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VITRS income statement (TTM) | |
|---|---|
| Revenue | SEK 3.54b |
| Cost of Revenue | SEK 1.46b |
| Gross Profit | SEK 2.08b |
| Other Expenses | SEK 1.63b |
| Earnings | SEK 455.00m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Oct 23, 2025
| Earnings per share (EPS) | 3.36 |
| Gross Margin | 58.85% |
| Net Profit Margin | 12.85% |
| Debt/Equity Ratio | 14.1% |
How did VITRS perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/04 17:56 |
| End of Day Share Price | 2025/10/01 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vitrolife AB (publ) is covered by 13 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| null null | ABG Sundal Collier Sponsored |
| Kallum Titchmarsh | BofA Global Research |